Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 19 April 2024 AM
One Big Pharma saw AU$65 billion in global revenue evaporate last year while combined, the Top 20 pharmas earned $71 billion less than the Top 20 the previous year.
Pfizer saw its revenue plummet by $65 billion (US$41.8 billion) to sell $91 billion(US$58.5 billion) in treatments in 2023. That 41.7 per cent fall from a high of $156 billion (US$100.3 billion) in revenue for 2022 revenue was expected, and directly attributable to the end of the Covid pandemic.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.